Anti-viral T-cell Therapy by Gamma Capture
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Paul Szabolcs, MD · PRINCIPAL_INVESTIGATOR · University of Pittsburgh
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Grade III-IV Acute GvHDDay 0
The number of patients who develop Grade III-IV acute graft versus host disease (GVHD) attributed to the viral specific T cells.
- Grade III-IV Acute GvHD1 month from first cellular infusion
The number of patients who develop Grade III-IV acute graft versus host disease (GVHD) attributed to the viral specific T cells.
- Grade III-IV Acute GvHD3 month from first cellular infusion
The number of patients who develop Grade III-IV acute graft versus host disease (GVHD) attributed to the viral specific T cells.
- Grade III-IV Acute GvHD6 month from first cellular infusion
The number of patients who develop Grade III-IV acute graft versus host disease (GVHD) attributed to the viral specific T cells.
- Clinical response to treatment of viral infection1 month from first cellular infusion
Rate of Elimination or reduction of oxygen dependence identified at baseline
- Clinical response to treatment of viral infection1 month from first cellular infusion
Rate of Resolution of diarrhea attributable to the viral disease, less than 4 stools daily
- Clinical response to treatment of viral infection1 month from first cellular infusion
Rate of Resolution of fever, attributable to viral disease
- Clinical response to treatment of viral infection1 month from first cellular infusion
Rate of Resolution or improvement of radiographic findings attributable to viral disease
- Clinical response to treatment of viral infection1 month from first cellular infusion
Rate of Resolution or improvement of lymphadenopathy attributable to EBV, and ophthalmic findings attributable to CMV retinitis
- Clinical response to treatment of viral infection3 month from first cellular infusion
Rate of Elimination or reduction of oxygen dependence identified at baseline
- Clinical response to treatment of viral infection3 month from first cellular infusion
Rate of Resolution of diarrhea attributable to the viral disease, less than 4 stools daily
- Clinical response to treatment of viral infection3 month from first cellular infusion
Rate of Resolution of fever, attributable to viral disease
- Clinical response to treatment of viral infection3 month from first cellular infusion
Rate of Resolution or improvement of radiographic findings attributable to viral disease
- Clinical response to treatment of viral infection3 month from first cellular infusion
Rate of Resolution or improvement of lymphadenopathy attributable to EBV, and ophthalmic findings attributable to CMV retinitis
- Clinical response to treatment of viral infection6 months from first cellular infusion
Rate of Elimination or reduction of oxygen dependence identified at baseline
- Clinical response to treatment of viral infection6 months from first cellular infusion
Rate of Resolution of diarrhea attributable to the viral disease, less than 4 stools daily
- Clinical response to treatment of viral infection6 months from first cellular infusion
Rate of Resolution of fever, attributable to viral disease
- Clinical response to treatment of viral infection6 months from first cellular infusion
Rate of Resolution or improvement of radiographic findings attributable to viral disease
- Clinical response to treatment of viral infection6 months from first cellular infusion
Rate of Resolution or improvement of lymphadenopathy attributable to EBV, and ophthalmic findings attributable to CMV retinitis